Molecule guides
Semaglutide: Acylated GLP-1 Analogue Design, Mechanism and Laboratory Use
Three engineering choices turned a peptide cleared in minutes into one that persists for days — what they were, what the receptor does, and which evidence applies to what.
Key facts
- CAS number: 910463-68-2
- Molecular formula: C187H291N45O59
- Molecular weight: 4113.58 g/mol
- Purity: ≥99% by HPLC; lot-matched COA available
- Form: Lyophilized powder, sealed glass vial with flip-off seal
- Storage: −20 °C, sealed and protected from light and moisture
- Available sizes: 2 mg · 5 mg · 10 mg · 15 mg · 20 mg · 30 mg · 50 mg · 10-vial kit · 10 x 5 mg
Semaglutide is a 31-residue synthetic version of human glucagon-like peptide-1, modified so that enzymes cannot break it down quickly and so that it clings reversibly to albumin — changes that turn a lifetime of minutes into one of days. Among agonists at the GLP-1 receptor it is probably the best documented in the literature, and it is the compound labs reach for by default when they want a long-lasting agonist that hits one incretin receptor and nothing else. We ship it as freeze-dried research-grade material in sealed vials, intended for in-vitro and preclinical use only.
Everything below summarises published findings on this molecule and on the licensed medicines built from it. Nothing here amounts to a protocol for use in humans.
Semaglutide in brief
Semaglutide belongs to the incretin mimetics — engineered peptides that reproduce the signalling of hormones the intestine puts out after eating. GLP-1 in its natural form survives barely a minute or two, because the enzyme DPP-4 severs it near the N-terminus almost immediately. The aim in designing semaglutide was to evade that enzyme without losing potency at its target, the GLP-1 receptor: a class B G-protein-coupled receptor present in pancreatic islets, in gastric tissue, on vagal afferent neurons, and in several nuclei of the hypothalamus and hindbrain. Its pharmacology stops there — GIP and glucagon receptors are untouched — and that narrowness is exactly what makes it such a useful single-receptor benchmark.
Origin and structure
The scaffold is GLP-1(7-37), and three engineering choices define what was added to it:
- Aib (alpha-aminoisobutyric acid) at position 8. Putting this non-natural residue where alanine would sit removes the bond DPP-4 attacks — the single largest source of instability in the native hormone.
- Arginine at position 34 in place of lysine. With only one lysine left available, acylation happens at a single defined position instead of producing a mixture of regioisomers.
- A C18 fatty diacid is attached at Lys26 through a γ-Glu unit and a short PEG-like linker. Binding to albumin is reversible, and while bound the peptide is sheltered from the kidney and from proteases, then released gradually — the basis of the long half-life reported for the licensed medicine.
We list CAS 910463-68-2, formula C187H291N45O59 and an average mass of 4113.58 Da. That last value is the one to keep at hand, because it turns milligrams into nanomoles when you prepare an assay stock. In a roughly 4,113 Da peptide, residual water and counter-ion change the actual amount of peptide in the vial by a noticeable margin, which is why net peptide content on the certificate tells you more than the nominal fill weight.
The proposed mechanism
The mechanism is unremarkable receptor pharmacology stretched over an unusually long exposure. Once bound, the GLP-1 receptor is held in its active conformation; Gs coupling raises cAMP; PKA and Epac2 signalling follow. Isolated islet studies report stronger insulin release that remains glucose-dependent — the response follows surrounding glucose rather than overriding it. That dependency is the signature of incretin signalling and the reason this class behaves differently from insulin secretion-promoting agents that fire irrespective of glucose.
Outside the pancreas, mapping and neuronal-activation studies place GLP-1 receptors in the arcuate nucleus, the nucleus of the solitary tract and the area postrema. Rodent work then reports reduced feeding and delayed gastric emptying, attributed to those central and vagal receptor populations rather than to any direct effect on adipose tissue. Semaglutide recruits beta-arrestin relatively weakly compared with its G-protein signalling, and a number of in-vitro papers tie that bias to sustained cAMP output with less receptor internalisation. For questions about biased agonism at class B GPCRs, it is one of the standard tool compounds.
What has been studied
The evidence falls into three distinct tiers, and reading this field honestly means never mixing them together.
- Cell and receptor assays. cAMP measurements, radioligand and fluorescent binding, arrestin recruitment, and imaging of internalisation in cells expressing the human receptor. This is where potency and selectivity numbers come from.
- Animal work. Feeding behaviour, gastric transit, islet morphology, hepatic lipid content and c-Fos mapping of neural activity in rats and mice, usually in diet-induced obesity models; findings in models of fatty liver disease and atherosclerosis have also been reported by several groups.
- Clinical trials of the licensed medicine. Published programmes include large randomised studies in weight management and type 2 diabetes plus cardiovascular outcome trials. They tested a regulated product, manufactured, formulated and prescribed under medical supervision. They inform us about the molecule; they say nothing about research-grade powder and confer no licence for use in people.
As of 2026, active research areas include liver and kidney endpoints, neuroinflammation, central GLP-1 receptor biology, and mechanistic comparisons against agonists that hit several receptors. Our GLP-1 and incretin pathway hub surveys the field.
Presentations available
A larger vial costs less per milligram but ties you to a single reconstitution, so picking a size really means deciding how many working aliquots your protocol needs. Sizes and current prices are on the semaglutide product page; the whole family sits in the GLP-1 and incretin peptides collection.
Reconstitution and storage at the bench
Material arrives as a dry cake and is usually taken up in bacteriostatic water for bench use. The following is a calculation of concentration, not a dosing instruction: 2 mL of diluent in a 10 mg vial gives 5 mg/mL (5,000 mcg/mL), so each 0.1 mL drawn moves 500 mcg of peptide. Aim the diluent at the glass wall rather than straight at the cake, and swirl instead of shaking — shaking a lipidated peptide encourages aggregation and denaturation at the air interface.
Unopened freeze-dried vials keep at −20 °C, dry and out of the light. Solutions are normally held at 2–8 °C and used inside the study window. Purity is lost most often through repeated freeze–thaw cycles, and that is the reason aliquoting into single-use portions at reconstitution is routine. The reconstitution guide covers the mechanics.
Purity, the COA and how to read it
At a minimum, look for four things on the certificate: a chromatogram with the area percentage of the main peak, a mass-spec value set against the calculated 4113.58 Da, the lot identifier, and when the testing was done. Two entries invite misreading. First, chromatographic purity is a ratio of peak areas — it says what fraction of the UV-absorbing species is your target, and nothing at all about the quantity of peptide supplied. For that you need net peptide content, the figure that discounts moisture and counter-ion. Second, the lot identifier has to be the one stamped on the label of the vial; paperwork belonging to a different batch is marketing material, not evidence. Our explainers on COAs and on HPLC purity work through both in detail.
Regulatory position
In its medicinal form, semaglutide is a prescription-only medicine authorised in the EU, the United States and many other markets, produced under pharmaceutical quality systems and used under medical supervision. Research-grade semaglutide is a different thing altogether: a reference chemical for laboratory investigation. Neither can stand in for the other. Our page on what that actually means sets out how the distinction stands in 2026.
Related peptides and comparisons
Its usual comparators are tirzepatide, which engages both GIP and GLP-1 receptors, and liraglutide, the shorter-acting palmitoylated forerunner on the same backbone — both are covered in semaglutide vs tirzepatide and liraglutide vs semaglutide. For agonists spanning more receptors still, see retatrutide.
Matching catalogue section: GLP-1 & Incretin Peptides
Questions
What sort of molecule is semaglutide?
A 31-residue synthetic peptide derived from GLP-1(7-37), with three changes: Aib at position 8, arginine replacing lysine at 34, and a C18 fatty diacid on Lys26 joined through a γ-Glu linker. Functionally it is a GLP-1 receptor mono-agonist and has no meaningful activity at the GIP or glucagon receptors.
Why does it last so much longer than native GLP-1?
Two separate design features. Placing Aib at position 8 deletes the bond DPP-4 attacks, so the enzyme that dismantles the natural hormone in a couple of minutes has nothing to cut. Separately, the fatty diacid makes the peptide bind albumin in a reversible fashion, keeping it out of the kidney's filtrate and letting it come off the carrier only gradually. In pharmacokinetic studies of the licensed medicine, the result is a half-life counted in days.
Is semaglutide interchangeable with tirzepatide?
No. They follow the same playbook — protease-resistant substitutions plus a fatty acid — but they are built on different scaffolds. Semaglutide is a 31-residue GLP-1 analogue acting at a single receptor; tirzepatide is a 39-residue peptide on a GIP backbone that acts at both the GIP and GLP-1 receptors.
Which molecular weight should stock calculations use?
For the free peptide our catalogue gives 4113.58 Da. Remember that a freeze-dried vial also contains a counter-ion and some residual water, so the real molarity of your stock comes from the net peptide content on the certificate of analysis rather than from the vial's nominal fill.
What are the storage requirements?
Freeze-dried powder: −20 °C, sealed, dry and dark. In solution: 2–8 °C, protected from light, used within the study window. Split it into aliquots at the time of reconstitution so the rest of the stock is not spoiled by repeated freezing and thawing.
Do the clinical results transfer to research-grade semaglutide?
No. Those studies tested an authorised medicine with its own formulation, excipients, manufacturing controls and clinical supervision.
What makes a complete semaglutide certificate?
A chromatogram quoting main-peak area percentage; a mass-spec result checked against the calculated mass; a net peptide content value; the batch identifier; and the date the testing was carried out. Above all, that batch identifier has to be identical to the one on the vial in your hands.